Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 19/20 | 0.67 |
| ▸ | MAOB | P27338 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbamic Acid SCHEMBL4990385 | 0.88 | AOC3 (0.64) | AOC3MAOB | |
| SCHEMBL4284480 | 0.87 | AOC3 (0.67) | AOC3MAOBKMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6197358 | 0.83 | AOC3 (0.69) | AOC3MAOB | |
| SCHEMBL3939958 | 0.82 | AOC3 (0.74) | AOC3MAOBKMT2ASMN1; SMN2 | |
| Carbamic Acid SCHEMBL3935711 | 0.82 | AOC3 (0.67) | AOC3MAOB | |
| SCHEMBL4890202 | 0.81 | AOC3 (0.73) | AOC3MAOBKMT2ASMN1; SMN2 | |
| SCHEMBL3939953 | 0.81 | AOC3 (0.73) | AOC3MAOBKMT2ASMN1; SMN2 | |
| SCHEMBL3934166 | 0.81 | AOC3 (0.85) | AOC3MAOBKMT2ASMN1; SMN2 | |
| SCHEMBL972163 | 0.81 | AOC3 (1.00) | AOC3MAOBKMT2ASMN1; SMN2 | |
| SCHEMBL972734 | 0.81 | AOC3 (0.85) | AOC3MAOBKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170770-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP 1) INHIBITOR | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170770-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP 1) INHIBITOR | VCAM1, VAPB, FLT1 | AOC3 402/4885MAOB 1593/4885KMT2A 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.